Compounds > etoposide
Page last updated: 2024-08-23

etoposide and niacinamide

etoposide has been researched along with niacinamide in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's2 (14.29)29.6817
2010's11 (78.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Berger, NA; Berger, SJ; Chatterjee, S; Hashimoto, H; Tsai, ML; Whitacre, CM1
Kang, MR; Kho, JH; Kim, EJ; Um, SJ1
Pappo, A; Paulino, AC1
Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM1
Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P1
Audrito, V; D'Arena, G; Deaglio, S; Gaidano, G; Gottardi, D; Laurenti, L; Malavasi, F; Rossi, D; Vaisitti, T1
Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W1
Assavalapsakul, W; Cho, IR; Chung, YH; Johnston, RN; Kaewpiboon, C; Kaowinn, S; Malilas, W; Moon, J; Srisuttee, R1
Dowlati, A; Fu, P; Halmos, B; Ma, P; Mekhail, T; Nickolich, M; Pennell, N; Sharma, N1
Cheong, J; Jung, HU; Kim, HY; Park, BS; Yoo, KS; Yoo, SH; Yoo, YH; Yun, I1
An, L; Chen, Y; Feng, F; Gao, X; Lu, Y; Qu, J; Sun, H; Wang, C; Wang, F; Yang, Y; Zeng, Z; Zhang, C1
Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP1
Gerber, JM; Grunwald, MR; Induru, R; McDonnell, MH1

Reviews

1 review(s) available for etoposide and niacinamide

ArticleYear
Cutaneous manifestations in leukemia patients.
    Seminars in oncology, 2016, Volume: 43, Issue:3

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dermatomycoses; Etoposide; Humans; Leukemia; Mastocytosis; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Skin Diseases, Bacterial; Skin Neoplasms; Sorafenib

2016

Trials

2 trial(s) available for etoposide and niacinamide

ArticleYear
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 71, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Sorafenib; Treatment Outcome

2014

Other Studies

11 other study(ies) available for etoposide and niacinamide

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences.
    Cancer research, 1995, Sep-01, Volume: 55, Issue:17

    Topics: Animals; Apoptosis; Cells, Cultured; Cricetinae; Cricetulus; Etoposide; Fibroblasts; Humans; Luciferases; NAD; Niacinamide; Poly Adenosine Diphosphate Ribose; Transcription, Genetic; Tumor Suppressor Protein p53; Up-Regulation

1995
Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity.
    Molecular cell, 2007, Oct-26, Volume: 28, Issue:2

    Topics: Acetylation; Amino Acid Sequence; Apoptosis; Base Sequence; Cell Nucleus; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Down-Regulation; Enzyme Inhibitors; Etoposide; G1 Phase; HCT116 Cells; HeLa Cells; Humans; Hydroxamic Acids; Molecular Sequence Data; Mutation; Naphthalenes; Niacinamide; Nuclear Proteins; Pyrones; Resting Phase, Cell Cycle; RNA Interference; RNA, Small Interfering; Sirtuin 1; Sirtuins; Transcription Factors; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53

2007
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine

2009
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
    Oncology reports, 2010, Volume: 24, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide

2010
Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.
    Cancer research, 2011, Jul-01, Volume: 71, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Cell Growth Processes; Drug Synergism; Etoposide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Niacinamide; Sirtuin 1; Tumor Suppressor Protein p53

2011
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
    Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Extract of Bryophyllum laetivirens reverses etoposide resistance in human lung A549 cancer cells by downregulation of NF-κB.
    Oncology reports, 2014, Volume: 31, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Kalanchoe; Niacinamide; Nitriles; Plant Extracts; RNA Interference; RNA, Small Interfering; Sirtuin 1; Sulfones; Transcription Factor RelA; Transcription, Genetic

2014
Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
    Cancer letters, 2014, Dec-01, Volume: 355, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cisplatin; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Viral; Hep G2 Cells; Hepatitis B virus; Humans; Interferon-alpha; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Protein Stability; Sorafenib; Trans-Activators; Transfection; Viral Regulatory and Accessory Proteins

2014
MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Current cancer drug targets, 2015, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Sorafenib

2015
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Biochimica et biophysica acta, 2016, Volume: 1860, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice, SCID; MicroRNAs; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quercetin; Receptor, Notch1; Signal Transduction; Sorafenib; Transfection; Xenograft Model Antitumor Assays

2016